-
【Immunity】A new combination of drugs combined with anti-PD-L1! Studies have found that this combination can overcome cancer immunotherapy resistance
Time of Update: 2023-02-01
Fluorescence microscopy of controlled tumors with PD1-IL2v for the treatment of tumorsThe researchers combined the immune cytokine PD1-IL2v with the immune checkpoint inhibitor anti-PD-L1 to enhance anti-tumor immunity against immunotherapy-resistant tumors.
-
Strong and strong combination, go to the new course to focus on advanced urothelial cancer immunocombination therapy
Time of Update: 2022-10-01
prefaceIn recent years, the treatment of advanced urothelial carcinoma drugs has made rapid progress, including immune checkpoint inhibitors, FGFR kinase inhibitors and a number of antibody-conjugated
-
Lancet: The effect of combination therapy in the treatment of diabetic peripheral neuropathy pain
Time of Update: 2022-09-06
OPTION-DM is a multicentre, randomized, double-blind, crossover trial in patients with DPNP with a mean daily Numerical Pain Score (NRS) of 4 or higher (on a scale of 0-10) from 13 UK centres .
-
The combination of the two immunotherapy combinations of Shishi Shiguibao has been approved by the FDA
Time of Update: 2021-03-03
BMS announced that the FDA has approved the PD-1 inhibitor Opdivo (nivolumab), in association with the CTLA-4 inhibitor Yeervoy (ipilimumab), to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorapinib.
-
Strong combination CD38 antibody/protease inhibitor combination therapy is FDA approved.
Time of Update: 2020-10-15
these two drugs are important representatives of protease inhibitors and CD38 antibody drugs respectively, both of which have been approved for the treatment of multiple myeloma.
CANDOR is the first randomized Phase 3 clinical trial to compare DKd with Kyprolis and Desemisson (Kd) combinations in R/R MM patients.
-
Leukemia: The combination of the drug quizatini in combination with dasatinyni may be effective in the treatment of acute myeloid leukemia.
Time of Update: 2020-08-28
Enzyme inhibitors, which close the replaceable survival path of cancer cells when they bind to another TKI called dasatinib, could be more effective in promoting leukemia cell death, and the results may help researchers develop new therapies to treat AML patients with the FRT3 gene mutation.
-
ASCO 2020: K-drug-combination lunvanini's "cola combination" re-emerges in renal transparent cell carcinoma
Time of Update: 2020-06-05
In Phase II clinical study Keynote-146, 104 patients with metastatic transparent cell renal cell carcinoma were treated Paboli-Zandi ( K drug) combined with lendatinib, also known as the cola comb
-
" combination of TheOpdivo and Yervoy combination of Time Squibb
Time of Update: 2020-06-03
CheckMate-040 is an ongoing open label, multi-queue study that is evaluating the efficacy and safety of Opdivo or Opdivo-based combination therapies in advanced HCC patients with or without viral hepa
-
This combination regimen may improve outcomes for patients with relapsed/refractory mantle cell lymphoma in China
Time of Update: 2023-02-03
A phase II clinical study evaluating the efficacy and cytotoxicity of ibrutinib monotherapy as a salvage treatment for patients with MCL showed that the overall response rate (ORR) was 68%, the complete response rate (CR) was 21%, and the follow-up for 27 months showed long-lasting efficacy and good safety.
-
InnoCare announces that Tafasitamab in combination with lenalidomide has been approved
Time of Update: 2023-02-03
On December 28, 2022, InnoCare (SSE: 688428; Hong Kong Stock Exchange code: 09969) today announced that tafasitamab in combination with lenalidomide has been approved by the Hong Kong Department of Health for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation.
-
Two combination therapies for lung cancer are released, significantly improving patient survival!
Time of Update: 2023-02-02
Significantly improves treatment outcomes 02 02 Not long ago, a phase 2 study in the United States showed that for metastatic non-small cell lung cancer with high expression of PD-L1, compared with PD-1 drug Zimberelimab alone, adding Domvanalimab and Etrumadenant can significantly improve treatment outcomes and patient survival.
-
An important treatment option for patients with 1q21+ relapsed/refractory multiple myeloma – isatuximab-based combination therapy
Time of Update: 2023-02-02
Figure 3Conclusion of the studyTwo separate phase III studies have now shown the same degree of improvement in PFS in combination with Isa in addition to standard care (Pd or Kd) in patients with 1q21+, 1q21 gain, and 1q21 amplification.
-
New directions of immune combination: exploration of PD-L1 inhibitors combined with PARP inhibitors in solid tumors
Time of Update: 2023-02-02
prefaceImmune checkpoint inhibitors (ICIs) are effective in the treatment of a variety of solid tumors as monotherapy or in combination with other drugs. Preclinical data and early clinical trials hav
-
VV116 appeared on NEJM for the second time: the best solution for the new crown in the future or "in combination with P drugs", and approval is near?
Time of Update: 2023-02-01
ON DECEMBER 29, THE NEW ENGENG JOURNAL OF MEDICINE (NEJM) PUBLISHED THE RESULTS OF THE PHASE 3 CLINICAL TRIAL OF JUNSHI VV116 "HEAD-TO-HEAD PFIZER POXLOVID" ONLINE. The results showed that VV116 was n
-
The new drug combination could be effective in treating often fatal childhood brain tumors
Time of Update: 2023-02-01
Researchers at the University of Colorado's Anschutz School of Medicine have discovered a combination of drugs that may provide a better prognosis for children diagnosed with MYC enlarged into medulloblastoma, a commonly fatal brain cancer.
